Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Davoud Ahmadvand

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Preparative Biochemistry & Biotechnology|February 27, 2019
Designing an ELP-intein system: toward a more realistic outlookSaeed Ranjbar, Fatemeh Rahbarizadeh, Davoud Ahmadvand
Immunological Investigations|January 20, 2011
Nanobody; an old concept and new vehicle for immunotargetingFatemeh Rahbarizadeh, Davoud Ahmadvand, Zahra Sharifzadeh
Protein Expression and Purification|October 4, 2016
Oligo-clonal nanobodies as an innovative targeting agent for cancer therapy: New biology and novel targeting systemsShahryar Khoshtinat Nikkhoi, Fatemeh Rahbarizadeh, Davoud Ahmadvand
Current Opinion in Biotechnology|March 23, 2011
Biological targeting and innovative therapeutic interventions with phage-displayed peptides and structured nucleic acids (aptamers)Davoud Ahmadvand, Fatemeh Rahbarizadeh, Seyed Moein Moghimi
Hybridoma (2005)|August 19, 2008
High-expression of monoclonal nanobodies used in the preparation of HRP-conjugated second antibodyDavoud Ahmadvand, Fatemeh Rahbarizadeh, Vahid Khoddami Vishteh
Preparative Biochemistry & Biotechnology|June 22, 2017
Optimization of an anti-HER2 nanobody expression using the Taguchi methodAlireza Farasat, Fatemeh Rahbarizadeh, Davoud Ahmadvand, et al.
Biochemical and Biophysical Research Communications|February 27, 2014
A nanobody directed to a functional epitope on VEGF, as a novel strategy for cancer treatmentZahra Farajpour, Fatemeh Rahbarizadeh, Bahram Kazemi, et al.
International Journal of Biological Macromolecules|November 10, 2025
Oligoclonal anti-HER2 nanobody-targeted exosomes as a nano carrier for doxorubicin delivery to HER2-positive breast cancer in vitro and in vivoManal Khaleel Al-Khafaji, Fatemeh Rahbarizadeh, Davoud Ahmadvand
Hybridoma (2005)|October 14, 2008
Production and characterization of a high-affinity nanobody against human endoglinDavoud Ahmadvand, Mohammad J Rasaee, Fatemeh Rahbarizadeh, et al.
Bioimpacts : BI|May 17, 2013
Heavy Chain Only Antibodies: A New Paradigm in Personalized HER2+ Breast Cancer TherapySeyed Moein Moghimi, Fatemeh Rahbarizadeh, Davoud Ahmadvand, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Preparative Biochemistry & Biotechnology|February 27, 2019
Designing an ELP-intein system: toward a more realistic outlookSaeed Ranjbar, Fatemeh Rahbarizadeh, Davoud Ahmadvand
Immunological Investigations|January 20, 2011
Nanobody; an old concept and new vehicle for immunotargetingFatemeh Rahbarizadeh, Davoud Ahmadvand, Zahra Sharifzadeh
Protein Expression and Purification|October 4, 2016
Oligo-clonal nanobodies as an innovative targeting agent for cancer therapy: New biology and novel targeting systemsShahryar Khoshtinat Nikkhoi, Fatemeh Rahbarizadeh, Davoud Ahmadvand
Current Opinion in Biotechnology|March 23, 2011
Biological targeting and innovative therapeutic interventions with phage-displayed peptides and structured nucleic acids (aptamers)Davoud Ahmadvand, Fatemeh Rahbarizadeh, Seyed Moein Moghimi
Hybridoma (2005)|August 19, 2008
High-expression of monoclonal nanobodies used in the preparation of HRP-conjugated second antibodyDavoud Ahmadvand, Fatemeh Rahbarizadeh, Vahid Khoddami Vishteh
Preparative Biochemistry & Biotechnology|June 22, 2017
Optimization of an anti-HER2 nanobody expression using the Taguchi methodAlireza Farasat, Fatemeh Rahbarizadeh, Davoud Ahmadvand, et al.
Biochemical and Biophysical Research Communications|February 27, 2014
A nanobody directed to a functional epitope on VEGF, as a novel strategy for cancer treatmentZahra Farajpour, Fatemeh Rahbarizadeh, Bahram Kazemi, et al.
International Journal of Biological Macromolecules|November 10, 2025
Oligoclonal anti-HER2 nanobody-targeted exosomes as a nano carrier for doxorubicin delivery to HER2-positive breast cancer in vitro and in vivoManal Khaleel Al-Khafaji, Fatemeh Rahbarizadeh, Davoud Ahmadvand
Hybridoma (2005)|October 14, 2008
Production and characterization of a high-affinity nanobody against human endoglinDavoud Ahmadvand, Mohammad J Rasaee, Fatemeh Rahbarizadeh, et al.
Bioimpacts : BI|May 17, 2013
Heavy Chain Only Antibodies: A New Paradigm in Personalized HER2+ Breast Cancer TherapySeyed Moein Moghimi, Fatemeh Rahbarizadeh, Davoud Ahmadvand, et al.
Pageof 6